NO20010196L - Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft - Google Patents

Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft

Info

Publication number
NO20010196L
NO20010196L NO20010196A NO20010196A NO20010196L NO 20010196 L NO20010196 L NO 20010196L NO 20010196 A NO20010196 A NO 20010196A NO 20010196 A NO20010196 A NO 20010196A NO 20010196 L NO20010196 L NO 20010196L
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
compositions
methods
prostate cancer
Prior art date
Application number
NO20010196A
Other languages
English (en)
Other versions
NO20010196D0 (no
Inventor
Davin Clifford Dillon
Susan Louise Harlocker
Jiang Yuqiu
Jiangchun Xu
Jennifer Lynn Mitcham
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/116,134 external-priority patent/US7008772B1/en
Priority claimed from US09/115,453 external-priority patent/US6657056B2/en
Priority claimed from US09/159,812 external-priority patent/US6613872B1/en
Priority claimed from US09/232,880 external-priority patent/US7270980B2/en
Priority claimed from US09/232,149 external-priority patent/US6465611B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20010196D0 publication Critical patent/NO20010196D0/no
Publication of NO20010196L publication Critical patent/NO20010196L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20010196A 1998-07-14 2001-01-12 Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft NO20010196L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/116,134 US7008772B1 (en) 1997-02-25 1998-07-14 Compounds for immunodiagnosis of prostate cancer and methods for their use
US09/115,453 US6657056B2 (en) 1997-02-25 1998-07-14 Compounds for immunotherapy of prostate cancer and methods for their use
US15982298A 1998-09-23 1998-09-23
US09/159,812 US6613872B1 (en) 1997-02-25 1998-09-23 Compounds for immunotherapy of prostate cancer and methods for their use
US09/232,880 US7270980B2 (en) 1997-02-25 1999-01-15 Compounds for immunodiagnosis of prostate cancer and methods for their use
US09/232,149 US6465611B1 (en) 1997-02-25 1999-01-15 Compounds for immunotherapy of prostate cancer and methods for their use
US28894699A 1999-04-09 1999-04-09
PCT/US1999/015838 WO2000004149A2 (en) 1998-07-14 1999-07-14 Compositions and methods for therapy and diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
NO20010196D0 NO20010196D0 (no) 2001-01-12
NO20010196L true NO20010196L (no) 2001-03-12

Family

ID=27568734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010196A NO20010196L (no) 1998-07-14 2001-01-12 Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft

Country Status (17)

Country Link
EP (2) EP1870466A3 (no)
JP (1) JP2002520054A (no)
KR (2) KR20010083111A (no)
CN (1) CN100419079C (no)
AU (2) AU762812B2 (no)
BR (1) BR9912007A (no)
CA (1) CA2334038A1 (no)
CZ (1) CZ2001149A3 (no)
HU (1) HUP0203035A3 (no)
IL (1) IL140845A0 (no)
NO (1) NO20010196L (no)
NZ (1) NZ509178A (no)
PL (1) PL200772B1 (no)
SA (1) SA99200618B1 (no)
TR (1) TR200100916T2 (no)
TW (2) TW200532020A (no)
WO (1) WO2000004149A2 (no)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2060630B1 (en) 1997-04-10 2012-10-24 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3 genes, and methods of use
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2629442T3 (es) 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
JP2002541803A (ja) * 1999-04-09 2002-12-10 コリクサ コーポレイション 乳癌の処置および診断のための組成物ならびに方法
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
WO2001004143A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Biologicals S.A. Prostase vaccine
DE60027027T2 (de) 1999-09-29 2006-11-30 Diagnocure Inc. Pca3 mrna in gutartigen und bösartigen prostatageweben
WO2001023577A2 (en) * 1999-09-30 2001-04-05 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
ES2371212T3 (es) * 1999-10-05 2011-12-28 Agensys, Inc. Receptor acoplado a proteína g regulado positivamente en el cáncer de próstata y usos del mismo.
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
EP1220931A1 (en) * 1999-10-07 2002-07-10 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
AU1656501A (en) * 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
JP2003528591A (ja) * 2000-01-14 2003-09-30 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
WO2001059110A2 (en) * 2000-02-08 2001-08-16 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CA2403909A1 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
US20050019340A1 (en) 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
PL365605A1 (en) 2000-11-28 2005-01-10 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1515982A4 (en) * 2001-05-09 2005-10-26 Corixa Corp METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (es) 2001-09-06 2015-03-31 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
AU2002258689C1 (en) * 2002-04-01 2008-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
CN100360558C (zh) * 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
AU2003250828A1 (en) * 2002-06-11 2003-12-22 Glaxo Group Limited Immunogenic compositions comprising a xenogenic prostate protein p501s
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5470848B2 (ja) 2006-08-04 2014-04-16 味の素株式会社 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
JP5746810B2 (ja) 2006-12-21 2015-07-08 味の素株式会社 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
WO2008075663A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
KR100976218B1 (ko) 2008-05-26 2010-08-17 한국표준과학연구원 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표
WO2009154297A1 (ja) 2008-06-20 2009-12-23 味の素株式会社 前立腺疾患の評価方法
KR101667319B1 (ko) 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
PT2324842E (pt) * 2008-08-05 2015-07-21 Toray Industries Agente de indução de imunidade
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
US8778621B2 (en) * 2009-05-12 2014-07-15 Koninklijke Philips N.V. Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018948B1 (pt) 2010-02-04 2021-12-14 Toray Industries, Inc Composições farmacêuticas, anticorpos, combinação farmacêutica, usos de uma composição farmacêutica, uso de um anticorpo e uso de uma combinação farmacêutica
CA2788720C (en) 2010-02-04 2019-08-20 Takayoshi Ido Medicament for treating and/or preventing cancer
US8937160B2 (en) 2010-02-04 2015-01-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
JP2014510721A (ja) 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
PL2740795T3 (pl) 2011-08-04 2017-04-28 Toray Industries, Inc. Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
PT2740798T (pt) 2011-08-04 2017-03-13 Toray Industries Composição de fármaco para o tratamento e/ou a prevenção de cancro
EP2740796B1 (en) 2011-08-04 2017-05-17 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
DK2740793T3 (en) 2011-08-04 2018-01-22 Toray Industries PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
PT2818481T (pt) 2012-02-21 2019-10-25 Toray Industries Composição farmacêutica para tratamento e/ou prevenção de cancro
CN104114583B (zh) 2012-02-21 2019-11-19 东丽株式会社 癌的治疗和/或预防用药物组合物
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
AU2013241043B2 (en) 2012-03-30 2017-11-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
IN2014DN10991A (no) * 2012-05-25 2015-09-25 Cellectis
PL2876446T3 (pl) 2012-07-19 2019-06-28 Toray Industries, Inc. Sposób wykrywania nowotworu
ES2769831T3 (es) 2012-07-19 2020-06-29 Toray Industries Método para detectar cáncer
RU2663350C2 (ru) 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины
EP2912069B1 (en) 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015020212A1 (ja) 2013-08-09 2015-02-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
WO2017200852A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
CA3067224A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
CA3119059A1 (en) * 2018-11-07 2020-05-14 Akouos, Inc. Compositions and methods of inducing differentiation of a hair cell
CN111000858B (zh) * 2019-05-10 2021-04-09 常州市第二人民医院 Nupr1抑制剂在制备膀胱癌治疗药物中的用途
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN111968751B (zh) * 2020-06-29 2021-10-19 金电联行（北京）信息技术有限公司 一种使用多基线校正模型的传染病趋势预测方法与系统
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
NZ236114A (en) * 1989-11-22 1993-04-28 Merrell Dow Pharma Peptide antagonists of bombesin and of gastrin releasing peptide, and pharmaceutical compositions
WO1996034012A1 (en) * 1995-04-28 1996-10-31 Takeda Chemical Industries, Ltd. Cyclic pentapeptide lh-rh receptor antagonists
AU728186B2 (en) * 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DK0972201T3 (da) * 1997-02-25 2006-01-02 Corixa Corp Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
AU731840B2 (en) * 1997-02-25 2001-04-05 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6130043A (en) * 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
EP1097208A2 (en) 2001-05-09
HUP0203035A3 (en) 2007-12-28
KR20070112860A (ko) 2007-11-27
CA2334038A1 (en) 2000-01-27
NZ509178A (en) 2004-04-30
BR9912007A (pt) 2002-01-29
IL140845A0 (en) 2002-02-10
AU5314899A (en) 2000-02-07
NO20010196D0 (no) 2001-01-12
CN1315998A (zh) 2001-10-03
EP1870466A2 (en) 2007-12-26
SA99200618B1 (ar) 2007-01-20
AU2003248213A1 (en) 2003-10-30
HUP0203035A2 (hu) 2002-12-28
EP1870466A3 (en) 2008-03-19
AU762812B2 (en) 2003-07-03
CZ2001149A3 (cs) 2002-02-13
JP2002520054A (ja) 2002-07-09
WO2000004149A3 (en) 2000-07-20
PL346359A1 (en) 2002-02-11
KR20010083111A (ko) 2001-08-31
CN100419079C (zh) 2008-09-17
WO2000004149A2 (en) 2000-01-27
TR200100916T2 (no) 2002-06-21
PL200772B1 (pl) 2009-02-27
TW200532020A (en) 2005-10-01
TW200728465A (en) 2007-08-01

Similar Documents

Publication Publication Date Title
NO20010196D0 (no) Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20016427D0 (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
NO20003853D0 (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
EP1515982A4 (en) METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
NO20013002D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
NO983183L (no) Blandinger og fremgangsmåte for behandling og diagnose av brystkreft
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1578380A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
NO20014769D0 (no) Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU4473596A (en) Methods of human prostate cancer diagnosis
EP1007535A4 (en) METHOD AND PREPARATIONS FOR DIAGNOSTIC AND TREATMENT OF BREAST CANCER
NO994932D0 (no) Blandinger og fremgangsmaater for behandling og diagnose av brystkreft
EP1129217A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES
EP1175616A4 (en) METHODS FOR DIAGNOSING AND TREATING METASTATIC PROSTATE TUMORS
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
NO20014804L (no) Forbindelser for immunterapi og diagnose av brystkreft og fremgangsmåter for deres anvendelse
GB9811598D0 (en) Diagnosis and treatment of cancer
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
NO20014805L (no) Blandinger og fremgangsmater for behandling og diagnose av brystkreft
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002332606A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application